Navigation Links
New dual recognition mechanism discovered in tuberculosis
Date:9/9/2010

One third of the world's population is infected with Mycobacterium tuberculosis (MTB), which leads to tuberculosis (TB), a leading cause of death world-wide. A new discovery, led by a team of researchers from Case Western Reserve University School of Medicine, offers hope for new approaches to the prevention and treatment of TB. The team's discovery of a novel mechanism that may contribute to immune recognition of MTB is published in the September issue of Nature Structural and Molecular Biology.

Most individuals with TB recover from the initial infection and become asymptomatic, but the bacterium persists for years, surviving largely inside macrophages, a type of cell that resides in the immune system. This presents a public health problem in that TB can reactivate and cause serious disease or death. Researchers and physicians know the body's immune system is capable of containing the infection but not curing it completely. It begs the question: "How does the organism survive in the human immune system for so many years?"

For the past 15 years, Drs. Clifford Harding and W. Henry Boom of Case Western Reserve have been seeking the answer to this question. Their work indicated that MTB can inhibit the ability of macrophages to stimulate infection-fighting immune responses, and they identified that a protein on macrophages called Toll-like receptor 2 (TLR2) is involved in this immune evasion mechanism. TLR2 seems to be a two-edged sword in the complex immune response to MTB, as it helps some immunity mechanisms and inhibits others. Understanding the balance of these effects and the role of TLR2 may provide insights to design therapies for TB.

"Understanding how MTB interacts with the immune system and how it can both activate and inhibit the immune response is critically important for the design of the next generation of TB vaccines. The persistence of infection is dependent on MTB's ability to manipulate our immune system to its advantage. The paradox here is that the MTB molecule, LprG, stimulates TLR2, one of the major receptors we have to identify disease-causing microorganisms. In this case, too much stimulation through TLR2 actually favors MTB by causing parts of the immune response to shut down," explains W. Henry Boom, MD, professor of medicine and director of the Tuberculosis Research Unit at Case Western Reserve School of Medicine.

The new studies show that the potency of LprG to induce these responses is explained by its combination of two mechanisms to activate TLR2: first, by directly stimulating TLR2 and, second, by serving as a carrier to deliver other molecules that stimulate TLR2. This dual mechanism may drive stronger regulation of immune responses by MTB, and future vaccine development may be enhanced by designing approaches to use such mechanisms. Furthermore, the work indicates that LprG contributes to the assembly of the bacterial cell wall, suggesting that it may be possible to develop molecules to interfere with LprG function and potentially serve as new antibiotics to fight TB. The development of new antibiotics is an increasingly important goal, since resistance to existing antibiotics is becoming widespread.

A multi-institutional partnership contributed to the overall success of this research initiative. Two important collaborative groups were led by James C. Sacchettini, PhD, Texas A&M University and D. Branch Moody, MD, Harvard Medical School. In addition, the project was spearheaded by Michael G. Drage and Nicole D. Pecora, two Case Western Reserve students in the MSTP Program, granting dual MD and PhD degrees, in collaboration with Jennifer Tsai, a graduate student in Dr. Sacchettini's group.

"Our research team is composed of several collaborative groups that each contributed key components to this project. The synergistic way in which the team interacted was a perfect example of scientists working together to advance the study of a disease that detrimentally impacts the lives of so many across the globe. We look forward to continuing to advance this research together," says Clifford V. Harding, MD, PhD, professor and interim chair of pathology at Case Western Reserve School of Medicine.

As they look to the future, the research team will work to gain a better understanding of immune responses in TB and hopefully design approaches to treat the deadly disease, including antibiotics or immunotherapies. Continued work will include study of the mechanism of immune-evasion by MTB with the hope of finding ways to reverse this mechanism so that it no longer causes a persistent infection.


'/>"/>

Contact: Jessica Studeny
jessica.studeny@case.edu
216-368-4692
Case Western Reserve University
Source:Eurekalert

Related medicine news :

1. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
2. Christiana Care Health System Achieves Magnet(R) Recognition
3. Pelosi Statement in Recognition of Women’s History Month
4. Quantros Releases Video in Recognition of National Patient Safety Week
5. Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting
6. US Wellness, Inc. Receives National Recognition for Laboratory Excellence
7. Medical Billers Celebrate Official Day Of Recognition On March 25, 2010 - USA
8. Prestigious recognition award recipients announced by AGA
9. Nursefinders Announces “Best Nurses of Baltimore” Recognition Program
10. ASGE recognizes 48 endoscopy units for quality as part of its Endoscopy Unit Recognition Program
11. Recognition at first glance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery Center is Saluted as ... that Plastic Surgeon Kiranjeet Gill has been awarded as one of the 15th annual ... that was started in 2003 to salute young achievers in Southwest Florida who have ...
(Date:9/21/2017)... ... ... SABRE is raising awareness about personal safety with a Chicago Transit Authority ... The Chicago, Illinois, based self-defense brand has been waiting for an opportunity like this ... their personal safety into their own hands. , The ads focus on their diverse ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, Keeping Up with ... In the competitive world of drug and device marketing and promotion, drug and ... rules. , The FDA has issued two draft guidances that are the closest ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... their communities, nine governmental public health departments have been awarded five-year accreditation status ... mean that the benefits of being served by a PHAB-accredited health department ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... or exercise more try taking a more holistic approach and use natural alternatives ... Amazon essential oil collection is certified USDA guaranteeing that, the new line of ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... that Mike Rice , President and CEO, will be ... Rodman & Renshaw 19 th Annual Global ... time (12:25 p.m. Pacific time). The conference is being held ...
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical stage ... Ideation and Behavior (ASIB), has been granted Fast Track status ... therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + ... pivotal trial of this sequential therapy targeting patients who are ... ...
Breaking Medicine Technology: